Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
Replimune Group Inc. shares (REPL) dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in skin cancer. The therapy, RP1, was studied in combination with cemiplimab, a Regeneron Pharmaceuticals Inc. (REGN) monoclonal antibody branded as Libtayo. The combination therapy showed a clinically meaningful improvement in response rate and duration in patients with cutaneous squamous cell carcinoma, compared with Libtayo alone, but the complete response rate fell short of the study's statistical significance threshold, Replimune said in a release. The trial will continue as planned to assess overall survival and other factors, the company said. Replimune also said it would halt development of its investigational RP2 and RP3 therapies in squamous cell carcinoma of the head and neck and colorectal cancer. As of Sept. 30, the company said it had cash and investments totaling $496.8 million, and the reshuffling of portfolio priorities is expected to extend its cash runway to early 2026. Replimune shares have dropped 55% in the year to date, while the S&P 500 has gained 19%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-05-23 0828ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track